{"title":"Risk Factors of White Blood Cell Progression Among Patients With Chronic Lymphocytic Leukemia at Felege Hiwot Referral Hospital, Bahir Dar, Ethiopia.","authors":"Gedam Derbew Addisia, Awoke Seyoum Tegegne, Denekew Bitew Belay, Mitiku Wale Muluneh, Mahider Abere Kassaw","doi":"10.1177/11769351211069902","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Leukemia is a type of cancers that start in the bone marrow and produce a serious number of abnormal white blood cells. Bleeding and bruising problems, fatigue, fever, and an increased risk of infection are among symptoms of the disease. The main objective of this study is to identify the determinant of the progression rate of white blood cells among patients with chronic lymphocytic leukemia at Felege Hiwot Referral Hospital (FHRH), Bahir Dar, Ethiopia.</p><p><strong>Methods: </strong>A retrospective study design was conducted on 312 patients with chronic lymphocytic leukemia at FHRH, Bahir Dar, Ethiopia under treatment from 1 January 2017 to 31 December 2019. A linear mixed-effects model was considered for the progression of the white blood cell data.</p><p><strong>Results: </strong>The estimated coefficient of the fixed effect intercept was 84.68, indicating that the average white blood cell (WBC) count of the patients was 84.68 at baseline time by excluding all covariates in the model (<i>P</i>-value <.001). Male sex (<i>β</i> = 2.92, 95% confidence interval [CI] 0.58, 0.5.25), age (<i>β</i> = .17, 95% CI 0.08, 0.28), widowed/divorced marital status (<i>β</i> = 3.30, 95% CI 0.03, 6.57), medium chronic lymphocytic leukemia (CLL) stage (<i>β</i> = -4.34, 95% CI -6.57, -2.68), high CLL stage (<i>β</i> = -2.76, 95% CI -4.86, -0.67), hemoglobin (<i>β</i> = .15, 95% CI 0.07, 0.22), platelet (<i>β</i> = .09, 95% CI 0.02, 0.17), lymphocytes (<i>β</i> = .16, 95% CI 0.03, 0.29), red blood cell (RBC) (<i>β</i> = .17, 95% CI 0.09, 0.25), and follow-up time (<i>β</i> = .27, 95% CI 0.19, 0.36) were significantly associated with the average WBC count of chronic lymphocytic leukemia patients.</p><p><strong>Conclusions: </strong>The finding showed that age, sex, lymphocytic, stage of chronic lymphocytic leukemia, marital status, platelet, hemoglobin, RBC, and follow-up time were significantly associated with the average WBC count of chronic lymphocytic leukemia patients. Therefore, health care providers should give due attention and prioritize those identified factors and give frequent counseling about improving the health of chronic lymphocytic leukemia patients.</p>","PeriodicalId":35418,"journal":{"name":"Cancer Informatics","volume":" ","pages":"11769351211069902"},"PeriodicalIF":2.4000,"publicationDate":"2022-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3b/1c/10.1177_11769351211069902.PMC8771732.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Informatics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/11769351211069902","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MATHEMATICAL & COMPUTATIONAL BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Leukemia is a type of cancers that start in the bone marrow and produce a serious number of abnormal white blood cells. Bleeding and bruising problems, fatigue, fever, and an increased risk of infection are among symptoms of the disease. The main objective of this study is to identify the determinant of the progression rate of white blood cells among patients with chronic lymphocytic leukemia at Felege Hiwot Referral Hospital (FHRH), Bahir Dar, Ethiopia.
Methods: A retrospective study design was conducted on 312 patients with chronic lymphocytic leukemia at FHRH, Bahir Dar, Ethiopia under treatment from 1 January 2017 to 31 December 2019. A linear mixed-effects model was considered for the progression of the white blood cell data.
Results: The estimated coefficient of the fixed effect intercept was 84.68, indicating that the average white blood cell (WBC) count of the patients was 84.68 at baseline time by excluding all covariates in the model (P-value <.001). Male sex (β = 2.92, 95% confidence interval [CI] 0.58, 0.5.25), age (β = .17, 95% CI 0.08, 0.28), widowed/divorced marital status (β = 3.30, 95% CI 0.03, 6.57), medium chronic lymphocytic leukemia (CLL) stage (β = -4.34, 95% CI -6.57, -2.68), high CLL stage (β = -2.76, 95% CI -4.86, -0.67), hemoglobin (β = .15, 95% CI 0.07, 0.22), platelet (β = .09, 95% CI 0.02, 0.17), lymphocytes (β = .16, 95% CI 0.03, 0.29), red blood cell (RBC) (β = .17, 95% CI 0.09, 0.25), and follow-up time (β = .27, 95% CI 0.19, 0.36) were significantly associated with the average WBC count of chronic lymphocytic leukemia patients.
Conclusions: The finding showed that age, sex, lymphocytic, stage of chronic lymphocytic leukemia, marital status, platelet, hemoglobin, RBC, and follow-up time were significantly associated with the average WBC count of chronic lymphocytic leukemia patients. Therefore, health care providers should give due attention and prioritize those identified factors and give frequent counseling about improving the health of chronic lymphocytic leukemia patients.
期刊介绍:
The field of cancer research relies on advances in many other disciplines, including omics technology, mass spectrometry, radio imaging, computer science, and biostatistics. Cancer Informatics provides open access to peer-reviewed high-quality manuscripts reporting bioinformatics analysis of molecular genetics and/or clinical data pertaining to cancer, emphasizing the use of machine learning, artificial intelligence, statistical algorithms, advanced imaging techniques, data visualization, and high-throughput technologies. As the leading journal dedicated exclusively to the report of the use of computational methods in cancer research and practice, Cancer Informatics leverages methodological improvements in systems biology, genomics, proteomics, metabolomics, and molecular biochemistry into the fields of cancer detection, treatment, classification, risk-prediction, prevention, outcome, and modeling.